Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing therapies for neuronal excitability disorders. Their focus areas include chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. The company's revenue is generated through the development and potential commercialization of their lead drug candidates, ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures. Additionally, they have preclinical pipeline programs, such as the Kv7 Program for pain, epilepsy, and depression, and Anxiolytic for the treatment of generalized anxiety disorder.

Products

• ETX-810 for chronic pain

• ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures

• Preclinical pipeline programs